Tumor microenvironment in Hodgkin lymphoma: novel prognostic factors for assessing disease evolution.
Epstein-Barr virus (EBV)
Hodgkin lymphoma
immunohistochemistry (IHC)
microenvironment
prognostic factors
Journal
Journal of medicine and life
ISSN: 1844-3117
Titre abrégé: J Med Life
Pays: Romania
ID NLM: 101477617
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
11
07
2023
accepted:
28
07
2023
medline:
1
12
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
ppublish
Résumé
Hodgkin lymphoma (HL) has become one of the most curable hematological neoplasia. Clinical and biological factors remain the main pillars guiding therapeutic strategies in HL. Recent studies have improved our understanding of the phenotype, the characteristics of histogenesis, and other possible mechanisms of lymphomagenesis, including the role of Epstein-Barr virus (EBV) infection. Tumor cells manipulate the microenvironment, allowing them to develop their malignant phenotype and evade the attack of the host's immune response so that the interaction between tumor cells and the reactive microenvironment determines not only the histological features but also the clinical-pathological characteristics and prognosis of these patients - essential for the development of future therapies targeting various other cellular components of the tumor microenvironment. This article aimed to evaluate the characteristics of the tumor microenvironment and malignant cells using histopathology and immunohistochemistry (IHC) techniques to highlight the association of EBV and to study the expression of characteristic antigens in malignant and non-malignant cells within the tumor mass (overexpression of BCL2 (B-cell lymphoma 2) in malignant cells, presence of PD1 (Programmed cell death Protein 1) on T lymphocytes, CD68+ macrophages in the tumor microenvironment, and presence of EGFR (epidermal growth factor receptor). The analysis of the data collected in this paper highlights several key parameters with prognostic value and statistical significance: the EBV infection at diagnosis, its association with low-intensity BCL2(+), the presence of CD68 with rosette formation, and the identification of specific vascularization patterns. The development of prognostic systems that take into account the integration of biological prognostic markers seems essential for a better risk stratification.
Identifiants
pubmed: 38024830
doi: 10.25122/jml-2023-0239
pii: JMedLife-16-1201
pmc: PMC10652678
doi:
Substances chimiques
Proto-Oncogene Proteins c-bcl-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1201-1210Informations de copyright
©2023 JOURNAL of MEDICINE and LIFE.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Diagn Pathol. 2020 Feb 4;15(1):10
pubmed: 32019558
Life Sci. 2021 Mar 1;268:118979
pubmed: 33421528
Biomedicines. 2022 Mar 01;10(3):
pubmed: 35327381
Turk Patoloji Derg. 2018;34(3):199-206
pubmed: 29708579
J Biol Chem. 2001 Feb 2;276(5):3222-30
pubmed: 11058584
J Clin Pathol. 2007 Dec;60(12):1342-9
pubmed: 18042690
Blood. 2012 Oct 18;120(16):3280-7
pubmed: 22948049
Mediterr J Hematol Infect Dis. 2014 Jul 05;6(1):e2014053
pubmed: 25045461
Blood Cancer J. 2021 Jul 9;11(7):126
pubmed: 34244478
Blood. 2002 Jun 15;99(12):4283-97
pubmed: 12036854
Lancet. 2021 Oct 23;398(10310):1518-1527
pubmed: 33493434
J Pathol. 2002 Aug;197(5):677-83
pubmed: 12210089
Pathol Res Pract. 2021 Mar;219:153370
pubmed: 33618247
EMBO J. 2001 Jun 1;20(11):2768-78
pubmed: 11387210
Leukemia. 2007 Jan;21(1):44-52
pubmed: 16990761
Hematol Oncol. 2019 Jun;37 Suppl 1:87-91
pubmed: 31187532
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Am J Hematol. 2016 Jun;91(4):434-42
pubmed: 27001163
Leukemia. 2005 Jun;19(6):894-900
pubmed: 15800675
Cancers (Basel). 2021 Jul 18;13(14):
pubmed: 34298810
Exp Hematol. 2011 Oct;39(10):1007-1017.e1
pubmed: 21767511
Front Oncol. 2022 Oct 27;12:1034398
pubmed: 36387159
Blood Cancer J. 2018 Jan 26;8(1):e622
pubmed: 29373571
Br J Cancer. 2000 Mar;82(5):1117-21
pubmed: 10737396
Sci Rep. 2020 Jun 10;10(1):9410
pubmed: 32523087
Leuk Lymphoma. 2013 Nov;54(11):2418-25
pubmed: 23432688
Blood. 1995 Aug 15;86(4):1493-501
pubmed: 7632957
J Clin Med. 2021 Mar 08;10(5):
pubmed: 33800409
Am J Surg Pathol. 2013 Aug;37(8):1242-51
pubmed: 23851330
Nat Rev Dis Primers. 2020 Jul 23;6(1):61
pubmed: 32703953
CA Cancer J Clin. 2018 Mar;68(2):116-132
pubmed: 29194581
Leuk Res. 2014 Aug;38(8):857-61
pubmed: 24957412
Ann Hematol. 2015 Sep;94(9):1545-52
pubmed: 26004934
Am J Cancer Res. 2020 Mar 01;10(3):727-742
pubmed: 32266087
Clin Cancer Res. 2013 Jul 1;19(13):3462-73
pubmed: 23674495
J Leukoc Biol. 2022 Sep;112(3):539-545
pubmed: 35060170
Leuk Lymphoma. 2014 Mar;55(3):558-64
pubmed: 23772669
N Engl J Med. 2010 Mar 11;362(10):875-85
pubmed: 20220182
Leuk Lymphoma. 2007 Oct;48(10):2014-21
pubmed: 17917969